A method and a kit for determining the amount of anammox bacteria in a bioreactor, comprising the steps of: i) removing a sample from the bioreactor; iii) mixing the sample with alkali; v) heating the samples to at least 60° C.; vi) separating solid components; vii) adding a reducing agent to the liquid phase; viii) measuring the translucence of the liquid phase in a spectrophotometer at three wavelengths ranging from 500 to 600 nm; ix) comparing the measured translucence to a reference spectrum.

A method and a kit for determining the amount of anammox bacteria in a bioreactor, comprising the steps of: i) removing a sample from the bioreactor; iii) mixing the sample with alkali; v) heating the samples to at least 60° C.; vi) separating solid components; vii) adding a reducing agent to the liquid phase; viii) measuring the translucence of the liquid phase in a spectrophotometer at three wavelengths ranging from 500 to 600 nm; ix) comparing the measured translucence to a reference spectrum.

Single dye fluorescent staining (with a membrane—associated dye such as FM 1-43 or FM 4 -64) and the combination of differences in both intensity and spectral emission discriminate live from inactivated/dead bacteria and provides for rapid and accurate detection of live bacteria in mixed populations.

Single dye fluorescent staining (with a membrane—associated dye such as FM 1-43 or FM 4 -64) and the combination of differences in both intensity and spectral emission discriminate live from inactivated/dead bacteria and provides for rapid and accurate detection of live bacteria in mixed populations.

The invention relates to methods for determining the severity of a disease caused by a coronavirus infection, comprising quantifying the level of cellular RNA of RNase P in a blood sample of a subject.

The invention relates to methods for determining the severity of a disease caused by a coronavirus infection, comprising quantifying the level of cellular RNA of RNase P in a blood sample of a subject.

A sensor device for use in sensing a change in a concentration of micro-organisms, comprises a waveguide interferometer having a sensing arm and a reference arm, a microfluidic channel for a fluid containing the micro-organisms, and a trapping arrangement in the microfluidic channel for physically trapping the micro-organisms when the fluid flows along the microfluidic channel so as to concentrate the micro-organisms in a sensing region of the microfluidic channel. The sensing arm is configured to guide sensing light, the reference arm is configured to guide reference light, and the waveguide interferometer is configured to interfere the sensing light with the reference light. The waveguide interferometer and the microfluidic channel are configured to allow the sensing light to interact with the fluid and the micro-organisms in the sensing region of the microfluidic channel.

A sensor device for use in sensing a change in a concentration of micro-organisms, comprises a waveguide interferometer having a sensing arm and a reference arm, a microfluidic channel for a fluid containing the micro-organisms, and a trapping arrangement in the microfluidic channel for physically trapping the micro-organisms when the fluid flows along the microfluidic channel so as to concentrate the micro-organisms in a sensing region of the microfluidic channel. The sensing arm is configured to guide sensing light, the reference arm is configured to guide reference light, and the waveguide interferometer is configured to interfere the sensing light with the reference light. The waveguide interferometer and the microfluidic channel are configured to allow the sensing light to interact with the fluid and the micro-organisms in the sensing region of the microfluidic channel.

The disclosure relates to a method for a non-invasive technique to analyze the fate of probiotics and commensal microbiota from the human upper gastrointestinal tract, namely the ileum. The invention further relates to methods for the enumeration and determination of mechanism of action of probiotics in a non-invasive manner from the end of the small intestine. A composition comprising a probiotic delivered in vivo to healthy individuals with an ileostomy bag is described.

The invention concerns methods for mapping microbial niches and their uses.